SENL101

SENL101 is an autologous anti-CD7 chimeric antigen receptor (CAR) T cell therapy. It consists of a preparation of a patient's own T lymphocytes that have been genetically engineered to express a CAR targeting the tumor-associated antigen CD7. This design enables the modified T cells to recognize and eliminate CD7-expressing malignant cells through immunostimulatory and antineoplastic mechanisms. SENL101 is being developed primarily for the treatment of relapsed or refractory CD7-positive hematolymphoid malignancies such as acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), and T-cell lymphoblastic lymphoma (T-LBL). The therapy aims to provide targeted cytotoxicity against cancerous cells while allowing recovery of normal immune cell populations post-treatment[1][2][3][4][5].

Other names

SENL101SENL-101SENL 101Senl_NS7CARSenl-T7Senl-T-7Senl-T 7NS7CAR-TNS-7CAR-TNS 7CAR-T